TVS-MOTOR-COMPANY
8.3.2024 14:18:29 CET | Business Wire | Press release
TVS Motor Company (TVSM) - a leading global automaker that operates in the two and three-wheeler segment - is showcasing its product range for Europe at the Salon du Deux Roues, Lyon till March 10, 2024. In being present at one of Europe’s premier auto expos, TVSM has announced its presence in France. The company has partnered with Emil Frey, a 100-year-old enterprise with extensive distribution network and deep market insights in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240308987266/en/
TVS Motor Company zone at Salon du Deux Roues, Lyon in France (Photo: Business Wire)
TVSM is the world’s fourth largest two and three wheeler manufacturer, and the third most valued by market cap. Its products already sell in 80 countries.
The company is putting on display the TVS Apache RR 310, TVS Apache RTR 310, TVS Ronin, its electric scooters - TVS iQube S, TVS X, and its performance scooter - TVS NTORQ. The mobility show will be an opportunity for visitors to discover these models which are already approved for Europe. It will allow entities interested in marketing the brand in France to interact with the French and Indian TVS teams present on site.
Speaking on the participation, Sharad Mohan Mishra, President, Strategy, TVS Motor Company, said, “Our participation marks a significant milestone. Engaging with enthusiasts at this esteemed event enhances our visibility in France. We invite attendees to explore our pavilion and witness TVS Motor’s engineering, quality, and design prowess.”
Visitors are invited to the TVS Motor zone in stand 3B2 located in Hall 3.1 at the Salon du Deux Roues 2024.
PRODUCT DETAILS
- TVS X - the world's most advanced connected, electric scooter proudly made in India. This revolutionary machine sets a new benchmark in the global electric mobility industry with stunning design, unmatched performance & cutting-edge tech features, carving out a new category.
- TVS iQube - TVSM's flagship electric two-wheeler launched in 2020. It has led the mass adoption of EV mobility in India.
- TVS Apache 310 Series - a result of the symbiotic partnership with BMW, stands as a testament to international collaboration.
- TVS Ronin - a ‘modern-retro’ motorcycle, designed ground up and is a lifestyle statement that takes inspiration from the modern, new-age rider. It is designed with style, technology, and riding experience to promote an unscripted lifestyle.
- TVS NTORQ - a premium scooter that boasts of superior performance backed by TVS Racing Pedigree.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240308987266/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom